Wellgistics prices $5M offering (7.14M shares + warrants at $0.70), partners with TheracosBio on Brenzavvy

Wellgistics Health, Inc.

Public offering of 7,142,862 common shares and warrants to purchase an equal number, at $0.70 per unit; gross proceeds ~$5M.
Offering closed Sept 29; H.C. Wainwright acted as placement agent, receiving $350K fee and 500K warrants at $0.875.
Company to use net proceeds for working capital, R&D, and potential acquisitions.
Strategic collaboration with TheracosBio to distribute diabetes drug Brenzavvy (bexagliflozin) via 6,500+ pharmacies starting Q4 2025.
Partnership aims to lower patient costs by bypassing PBMs; Q4 rollout expected to generate near-term revenue.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.